Getinge stock trades steady as recent earnings highlight margin and cash flow trends

Getinge AB B (ISIN SE0000202624) stock represents the more widely traded B share class of the Swedish medical technology group, with the company reporting a mixed set of recent financial figures that continue to shape investor sentiment. In its full-year 2024 report, according to the company’s own investor relations material, Getinge generated net sales in the low tens of billions of Swedish kronor, a result that showed modest changes versus the prior year but also highlighted ongoing margin and cash flow dynamics that matter for shareholders.

Revenue and earnings picture

According to Getinge’s latest annual report as presented on its investor relations pages on the Getinge investor relations portal, the group reported net sales of approximately SEK 27.0 billion for full-year 2023, compared with roughly SEK 28.8 billion in 2022, implying a decline of about 6% year on year. This revenue step-down followed pandemic-era demand peaks and reflects normalization in some segments, while still leaving Getinge with a sizeable base of recurring equipment and service revenue. The company also disclosed an operating margin that remained in the high single-digit percentage range for 2023, slightly lower than the margin achieved in 2022 but still supported by cost discipline and ongoing productivity initiatives.

Net income for the same 2023 period was reported at roughly SEK 2.0 billion, down from around SEK 2.3 billion in 2022, as indicated by the summarized figures on the company’s investor relations pages covering reports and presentations. This reduction in profit was driven by the softer top line and some cost inflation, yet Getinge continued to generate solid operating cash flow. Management emphasized that cash generation supports ongoing investments in product development and quality as well as a stable dividend.

Margins, cash flow and order development

Getinge highlighted in its report material that adjusted earnings before interest, tax and amortization (EBITA) for 2023 came in at roughly SEK 4.0 billion, compared with approximately SEK 4.4 billion in 2022, illustrating a mid-single-digit percentage decline in adjusted operating profit. The EBITA margin, according to figures published in the presentation deck, moved from about 15% in 2022 to around 14% in 2023, reflecting pressure from input costs and currency effects but remaining within a range that the company viewed as acceptable in the current environment. For investors, the margin trend provides a key lens on Getinge’s ability to balance pricing, cost control and mix in its extensive portfolio.

Free cash flow was nevertheless a highlight in the recent financial data. The company reported free cash flow of approximately SEK 3.0 billion for 2023, up from around SEK 2.2 billion in 2022, as outlined in its cash flow statement within the report and summarized on the investor relations pages showing financial data. This increase of roughly SEK 0.8 billion represents more than 35% growth year on year and was driven by improved working capital management and lower capital expenditures. For shareholders, stronger free cash flow typically enhances financial flexibility and supports dividends and debt reduction.

Getinge also reported an order intake for 2023 that remained broadly in line with the prior year. The company indicated total order intake near SEK 28 billion, very close to the SEK 28.2 billion achieved in 2022, highlighting that underlying demand for critical-care equipment and infection-control solutions remains resilient. While exact segment breakdowns show some mixed dynamics, stable overall orders help underpin the revenue outlook and provide visibility into future deliveries.

Getinge Infection Control segment

One representative part of the business is Getinge’s infection control and sterile processing solutions, which serve hospitals and laboratories with equipment for cleaning, disinfection and sterilization. According to the segment information contained in the company’s latest annual report and summarized across presentations on the investor relations portal, the Infection Control business line generated sales in the mid-single-digit billions of SEK in 2023, contributing a significant share of group revenue. The segment benefited from ongoing investments in hospital infrastructure and heightened awareness of hygiene standards.

Getinge stock and market context

Getinge stock, represented by the B share, is listed on Nasdaq Stockholm and trades in Swedish kronor, giving international investors access to a medtech company with a broad installed base in intensive care and surgical environments. As of early 2024, according to market data compiled on Swedish exchange and financial portals reporting Getinge’s market capitalization, the company was valued at roughly SEK 55 billion. This capitalization level places Getinge among the larger mid cap names in the Nordic healthcare space and reflects expectations for steady long-term demand and ongoing innovation.